Butterfly Network's Chief Business Officer Steve Cashman sold 399,461 shares (19.68% of his direct holdings) for approximately $1.9 million in June 2026. The sale marks his largest single open-market transaction to date. While the stock has surged 291.8% over the past year, the analyst suggests the recent rally may have already priced in future g...

Ventripoint Diagnostics announced support for the newly formed Global Congenital Heart Disease Alliance (GCHDA), positioning its AI-powered VMS+ cardiac imaging platform to address a critical global healthcare gap. With 16 million people living with congenital heart disease and over 90% of children in lower-income countries lacking timely care, V...

Ventripoint Diagnostics has achieved multiple validation milestones in early 2026, including submitting its VMS+ 4.0 system to China's NMPA for expedited review, exhibiting at Europe's largest congenital cardiology conference, and establishing commercial partnerships for hospital deployment. The company is capitalizing on a shifting procurement e...

Hospital networks are increasingly adopting AI-enhanced cardiac imaging technologies to reduce costs and improve patient outcomes. The AI medical imaging market is projected to reach nearly $20 billion by 2033, with echocardiography expected to grow to $2.64 billion by 2030. Key players including VentriPoint Diagnostics, Butterfly Network, Tempus...

AI-driven clinical intelligence is transforming medical imaging, with point-of-care diagnostics projected to reach $70.92 billion by 2032. The CMS ACCESS Model launching in July 2026 will reward outcome-based care, driving adoption of software-defined imaging platforms. Key players including VentriPoint Diagnostics, Butterfly Network, Hyperfine, ...